Replies to post #602539 on NorthWest Biotherapeutics Inc (NWBO)

[Horseb4CarT]

Not to be argumentative but I can’t make that assertion because it’s not a self contained situation, with external parties and decision factors, and once revealed I have retrospectively agreed with management decisions such as extending the trial data collection to capture actual 5 year trial results versus using projected values, as an example.

Also as previously stated the share price isn’t a free market variable but in my opinion has been manipulated. So that could change however when is hard to predict.

I have and remain out on the limb in that I believe UK approval happens this year and sooner later, and the stock price will rise.

[Maverick0408]

They are here out of altruism and don’t care about the return on investment and importantly opportunity cost.

As I stated earlier, 2023 will be another lost year. The loyal supporters would like us to buy into one of the theories detailed below while the management continues to be ambiguous and keep shareholders in the dark to avoid mass exodus for their lack of meaningful progress:

1) The focus has shifted to FDA now? UK not number one priority anymore. So need more time to line up CRL and other million BLA pages?

2) Now applying strategically via Project Orbis. All RAs at once. Need extra months.

3) Flaskworks certification given off label demand considerations!

4) Tissue agnostic approvals.

5) No MAA acceptance PR. Need to wait until final MHRA approval (in 2024?) for the big reveal!